There are only a few currently FDA-approved anti-obesity medications and – except for GLP1-analogues – they produce only moderate weight loss (< 10%) and have adverse side effect profiles [18]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.